SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Theragenics Corporation

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Theragenics Corporation (“Theragenics” or the “Company”) (NYSE: TGX) relating to the proposed acquisition by Juniper Investment Company.

Click here to learn more about the investigation http://brodsky-smith.com/590-tgx-theragenics-corporation.html, or call 877-534-2590. There is no cost or obligation to you.

Under the terms of the transaction, Theragenics shareholders will receive only between $2.25 and $2.30 in cash for each share of Theragenics stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Theragenics for not acting in the Company’s shareholders' best interests in connection with the sale process. The transaction may undervalue the Company as Theragenics has a reported book value of $2.66 per share.

If you own shares of Theragenics common stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, by visiting http://brodsky-smith.com/590-tgx-theragenics-corporation.html, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Theragenics (NYSE:TGX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024